The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca; MedImmune
Travel, Accommodations, Expenses - MedImmune
Other Relationship - MedImmune
 
Employment - Amplimmune
Patents, Royalties, Other Intellectual Property - Amplimmune; Five Prime Therapeutics; Millennium; Xencor
Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
 
Omid Hamid
Research Funding - MedImmune (Inst)
 
Laura Quan Man Chow
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly/ImClone (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); VentiRx (Inst)
Travel, Accommodations, Expenses - Merck; Novartis
 
Fatemeh Tavakkoli
No Relationships to Disclose
 
Shannon Marshall
No Relationships to Disclose
 
Matthew Joseph Gribbin
Employment - MedImmune
Stock and Other Ownership Interests - MedImmune
Travel, Accommodations, Expenses - MedImmune
 
Joyson Joseph Karakunnel
Employment - Suburban Hosptial
Patents, Royalties, Other Intellectual Property - MedImmune
Other Relationship - MedImmune
 
Jhanelle Elaine Gray
Research Funding - MedImmune (Inst)